Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.4.0.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2016
Mar. 31, 2015
Revenues $ 379 $ 349 $ 673 $ 1,535
Operating expenses:        
Research and development (related party of $244, $258, $723 and $738) 1,048 815 2,303 2,731
General and administrative (related party of $296, $0 $374 and $0) 2,403 1,222 5,509 3,574
Total operating expenses 3,451 2,037 7,812 6,305
Operating loss (3,072) (1,688) (7,139) (4,770)
Other income (expense):        
Interest expense (related party of $323, $0, $323 and $0) (323) 0 (323) 0
Interest income 5 2 9 6
Royalty income 5 9 17 24
Total other income (expense) (313) 11 (297) 30
Consolidated net loss (3,385) (1,677) (7,436) (4,740)
Net loss attributable to noncontrolling interest 349 0 349 0
Net loss attributable to iBio, Inc. (3,036) (1,677) (7,087) (4,740)
Comprehensive loss:        
Consolidated net loss (3,385) (1,677) (7,436) (4,740)
Other comprehensive income (loss) - foreign currency translation adjustments 2 (12) (6) (26)
Comprehensive loss $ (3,383) $ (1,689) $ (7,442) $ (4,766)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted (in dollars per share) $ (0.04) $ (0.02) $ (0.09) $ (0.07)
Weighted-average common shares outstanding - basic and diluted (in shares) 81,158 72,989 78,587 69,913